Approximately, 40% of patients diagnosed with NSCLC will develop brain metastasis (BM) during the course of their disease and this risk may be even higher in those with adenocarcinoma with epidermal growth factor receptor (EGFR) mutation [1, 2]. The gene discussed is EGFR; the disease is adenocarcinoma.